Floatz logo

Pidnarulex

Double-Expressor Lymphoma

National Cancer Institute (NCI)Small moleculePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

71 Active assets in the Double-Expressor Lymphoma cohort.

Asset / SponsorPhaseRating
Axicabtagene Ciloleucel
Zhejiang Cancer Hospital
Phase 4BB
Cyclophosphamide
M.D. Anderson Cancer Center
Phase 4BB
Fludarabine
M.D. Anderson Cancer Center
Phase 4BB
ETOPOSIDE
University of California, Davis
Phase 2/3BB
Inno-206
Ruijin Hospital
Phase 3BB

View all 50 →

Same molecule, other indications

Pidnarulex is also rated in:

colorectal cancerDormant
CCC
Indicative ·
48 / 100
View asset →
Burkitt lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
high grade B-cell lymphoma with MYC and/ or BCL2 and/or BCL6 rearrangementDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →